Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
CSPC will receive an upfront payment of $100 million from AstraZeneca
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
India has taken the lead in recognising NAFLD as a major non-communicable disease
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Subscribe To Our Newsletter & Stay Updated